Overweight rheumatoid arthritis patients displayed lower remission rates and required twice as much drug therapy compared to normal weight patients.

All of the patients received a weekly dose of up to 25mg of methotrexate, with or without steroids, followed by a combination with a tumor necrosis factor (TNF) blocker if a response of good or better. The researchers also recorded the body mass index (BMI) of the patients along with ACR/EULAR core data while clinical remission was evaluated on each visit.
The researchers found that lower remission rates were sustained for a longer period among overweight and obese patients with more number of patients also undergoing anti-TNF therapy for 12 months of follow-up compared to normal weight patients. “Data suggest that in ERA patients, not only obesity but also overweight, associates with a lower percentage of success in obtaining remission”, the researchers wrote in their report.
Source-Medindia
MEDINDIA




Email








